Second generation BMP2 for dental surgical applications

The intern will be producing a therapeutic protein, i.e. ‘biologic’ (BMP2) using mutated

bacterial plasmids as the bio-factory. The intern will create a sequence of DNA to be

transformed into E. coli cells (BL21). The cells will be grown up in the lab, and studied for

enhanced clinical efficacy. Proteins will be affinity purified and the resulting BMP2 variants

will be tested in lab bioactivity assays. With a more potent mutant BMP2, our partner will be

able to increase the number of successful implantation and reconstruction services they offer

as a smaller physical quantity of BMP2 will reduce illicit adverse immune events.

Faculty Supervisor:

Illimar Altosaar

Student:

Partner:

Dr Hassan Ghaderi Moghadam Professional Corporation

Discipline:

Life Sciences

Sector:

University:

University of Ottawa

Program:

Accelerate

Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects